Abstract
Type-1 Diabetes is generally treated with exogenous insulin administration. Despite treatment, a very common long term consequence of diabetes is the development of a disabling and painful peripheral neuropathy. The transplantation of pancreatic islets is an advanced alternative therapeutic approach, but its clinical application is still very limited, mainly because of the great number of islets required to complete the procedure and of their short-term survival. An intriguing method to improve the performance of pancreatic islets transplantation is the co-transplantation of Mesenchymal Stem Cells (MSCs), adult stem cells already known to support the survival of different cellular populations. In this proof-of-concept study, we demonstrated using an in vivo model of diabetes, the ability of allogenic MSCs to reduce the number of pancreatic islets necessary to achieve glycemic control in diabetic rats, and overall their positive effect on diabetic neuropathy, with the reduction of all the neuropathic signs showed after disease induction. The cutback of the pancreatic islet number required to control glycemia and the regression of the painful neuropathy make MSC co-transplantation a very promising tool to improve the clinical feasibility of pancreatic islet transplantation for diabetes treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 75-84 |
| Number of pages | 10 |
| Journal | Experimental Neurology |
| Volume | 288 |
| DOIs | |
| Publication status | Published - Feb 1 2017 |
Fingerprint
Keywords
- Diabetes
- Diabetic neuropathy
- Mesenchymal stem cell
- Pancreatic islet transplantation
ASJC Scopus subject areas
- Neurology
- Developmental Neuroscience
Cite this
Therapeutic potential of Mesenchymal Stem Cells for the treatment of diabetic peripheral neuropathy. / Monfrini, Marianna; Donzelli, Elisabetta; Rodriguez-Menendez, Virginia; Ballarini, Elisa; Carozzi, Valentina Alda; Chiorazzi, Alessia; Meregalli, Cristina; Canta, Annalisa; Oggioni, Norberto; Crippa, Luca; Avezza, Federica; Silvani, Sara; Bonandrini, Barbara; Figliuzzi, Marina; Remuzzi, Andrea; Porretta-Serapiglia, Carla; Bianchi, Roberto; Lauria, Giuseppe; Tredici, Giovanni; Cavaletti, Guido; Scuteri, Arianna.
In: Experimental Neurology, Vol. 288, 01.02.2017, p. 75-84.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Therapeutic potential of Mesenchymal Stem Cells for the treatment of diabetic peripheral neuropathy
AU - Monfrini, Marianna
AU - Donzelli, Elisabetta
AU - Rodriguez-Menendez, Virginia
AU - Ballarini, Elisa
AU - Carozzi, Valentina Alda
AU - Chiorazzi, Alessia
AU - Meregalli, Cristina
AU - Canta, Annalisa
AU - Oggioni, Norberto
AU - Crippa, Luca
AU - Avezza, Federica
AU - Silvani, Sara
AU - Bonandrini, Barbara
AU - Figliuzzi, Marina
AU - Remuzzi, Andrea
AU - Porretta-Serapiglia, Carla
AU - Bianchi, Roberto
AU - Lauria, Giuseppe
AU - Tredici, Giovanni
AU - Cavaletti, Guido
AU - Scuteri, Arianna
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Type-1 Diabetes is generally treated with exogenous insulin administration. Despite treatment, a very common long term consequence of diabetes is the development of a disabling and painful peripheral neuropathy. The transplantation of pancreatic islets is an advanced alternative therapeutic approach, but its clinical application is still very limited, mainly because of the great number of islets required to complete the procedure and of their short-term survival. An intriguing method to improve the performance of pancreatic islets transplantation is the co-transplantation of Mesenchymal Stem Cells (MSCs), adult stem cells already known to support the survival of different cellular populations. In this proof-of-concept study, we demonstrated using an in vivo model of diabetes, the ability of allogenic MSCs to reduce the number of pancreatic islets necessary to achieve glycemic control in diabetic rats, and overall their positive effect on diabetic neuropathy, with the reduction of all the neuropathic signs showed after disease induction. The cutback of the pancreatic islet number required to control glycemia and the regression of the painful neuropathy make MSC co-transplantation a very promising tool to improve the clinical feasibility of pancreatic islet transplantation for diabetes treatment.
AB - Type-1 Diabetes is generally treated with exogenous insulin administration. Despite treatment, a very common long term consequence of diabetes is the development of a disabling and painful peripheral neuropathy. The transplantation of pancreatic islets is an advanced alternative therapeutic approach, but its clinical application is still very limited, mainly because of the great number of islets required to complete the procedure and of their short-term survival. An intriguing method to improve the performance of pancreatic islets transplantation is the co-transplantation of Mesenchymal Stem Cells (MSCs), adult stem cells already known to support the survival of different cellular populations. In this proof-of-concept study, we demonstrated using an in vivo model of diabetes, the ability of allogenic MSCs to reduce the number of pancreatic islets necessary to achieve glycemic control in diabetic rats, and overall their positive effect on diabetic neuropathy, with the reduction of all the neuropathic signs showed after disease induction. The cutback of the pancreatic islet number required to control glycemia and the regression of the painful neuropathy make MSC co-transplantation a very promising tool to improve the clinical feasibility of pancreatic islet transplantation for diabetes treatment.
KW - Diabetes
KW - Diabetic neuropathy
KW - Mesenchymal stem cell
KW - Pancreatic islet transplantation
UR - http://www.scopus.com/inward/record.url?scp=84995752904&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84995752904&partnerID=8YFLogxK
U2 - 10.1016/j.expneurol.2016.11.006
DO - 10.1016/j.expneurol.2016.11.006
M3 - Article
AN - SCOPUS:84995752904
VL - 288
SP - 75
EP - 84
JO - Experimental Neurology
JF - Experimental Neurology
SN - 0014-4886
ER -